HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU health claims

This article was originally published in The Tan Sheet

Executive Summary

The European Food Safety Authority published its final guidance for applicants on the submission of health claims July 26. The guidance says the application must contain information such as the characteristics of the food for which a health claim is made, a proposal for the wording of the health claim, including the specific conditions for use, all pertinent scientific data, the cause and effect relationship between the consumption of the substance and the claimed effect in humans and more. The pre-submission guidance came out in March (1"The Tan Sheet" March 26, 2007, p. 12). EFSA says 300 comments were received for its draft guidance...

You may also be interested in...

Manufacturers Embrace European Guidance On Health Claims

European health product manufacturers expect "pre-submission guidance" adopted by the European Food Safety Authority on applications for authorizing health claims will benefit the industry without imposing significant cost burdens

FDA Slacking In NDI Notification Enforcement; COVID-19 'Is Not An Excuse’ – NPA

In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.

Finance Watch: Four IPOs In One Week, And Legend Is Year’s Largest So Far

Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts